Lupin Ltd
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
845 / 1328
Position in country
2711 / 4091
Net income margin, %
11.9
2.8
EBITDA margin, %
19.6
10.8
Revenue CAGR 3Y, %
2.6
8.5
Revenue Y, % chg
16.8
0.5
P/E
41.3
22.7
P/BV
5.5
1.5
P/S
3.7
2.3
EV/S
3.8
2.4
EV/EBITDA
22.1
7.4
Average Analyst recommendation
Sell
Sell
Average upside forecasts, %
-10
51.3
Forward P/E
32.4
15.6
Dividend Yield, %
0.2
1.7
Forward Dividend Yield, %
0
0.2
Expected dividend per share
0
0
Dividend Ex Date
2023-07-14
Competitors
Ranks
-
Sun Pharmaceutical Industries Ltd
00%
-
Cipla Ltd
00%
-
Torrent Pharmaceuticals Ltd
00%
-
Zydus Lifesciences Ltd
00%
-
Dr Reddy's Laboratories Ltd
00%
-
Alkem Laboratories Ltd
00%
-
Aurobindo Pharma Ltd
00%
-
IPCA Laboratories Ltd
00%
-
Lupin Ltd
00%
-
Mankind Pharma Ltd
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
India
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Sub-sector
Health Care
Capitalization (millions of $)
8871.9
Ticker
LUPN.NS
ISIN
INE326A01037
IPO date
1994-11-30
Availability on Russian exchanges
No
Reporting for
2024-02-07
Date fact. publication of reports
2023-12-31
Company Description
Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas. The Company also offers solutions in the anti-tuberculosis (anti-TB) and cephalosporins therapy areas. The Company along with its subsidiaries has manufacturing locations spread across India, Japan, the United States, Mexico and Brazil. It has a pipeline of biosimilars addressing therapies, such as oncology, anti-inflammatory, anti-viral, rheumatoid arthritis, endocrinology, diabetes, ophthalmology and women's health. The Company's products include Antara, Methergine, Methylphenidate, Glumetza, Gluconorm, Tonact, Rcinex and Ramistar, among others.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: